Navigation Links
Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder

Phase 3 trials conducted on Remicade (infliximab) showed rapid, significant improvement in patients with moderate to severe plaque psoriasis. The stud mainly used placebo-// control and dose-ranging from 3 mg/kg and 5 mg/kg. The continuous eight week maintenance therapy resulted in greater long-term skin clearance compared with as-needed therapy regimens within each dose.

At 10 weeks it was seen that 70 % of the patients treated with Remicade 3 mg/kg and 75 % of patients receiving 5 mg/kg achieved at least 75 % improvement in psoriasis. The measurement scale used was Psoriasis Area Severity Index (PASI 75). At the end of the 50 weeks patients receiving Remicade 5 mg/kg every eight-week maintenance therapy saw the highest level of improvement. The results were presented at the 64th annual American Academy of Dermatology meeting.

Alan Menter, MD, chairman, Division of Dermatology, Baylor University Medical Center, and lead study investigator said that patients receiving scheduled Remicade maintenance therapy achieved long-term cure against psoriasis, a lifelong, chronic inflammatory disease. Statistics show that nearly two million Americans suffer from this disease.

Robert Matheson, MD, Oregon Medical Research Center, and study investigator said that Remicade in the treatment of a disease offers great physical and emotional challenges. It has a potential to result in complete skin clearance.

The United States Food and Drug Administration (FDA) accepted the use of Remicade in the treatment of moderate to severe plaque psoriasis. Hence the European Commission also approved Remicade for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to other systemic therapy.


Page: 1

Related medicine news :

1. Remicade Therapy Effective in Treating Severe Psoriasis
2. Sanitation Emerges as the Winner
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Treatment for Menieres disease
6. Treatment for pre-menstrual syndrome is ineffective
7. Better Treatment for obesity
8. Gene Treatment for Heart Disease
9. More People Seeking Treatment for Depression
10. Focused Treatment For Childhood Cancer
11. Inadequate Drug Treatment For Youth
Post Your Comments:

(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: